wakey wakey mr market, page-47

Good job boiler.

Judging by how few of us holders were aware of the fact the US Institute of Health site records a start date of Jan 2012 for the phase 111 trial, the broader market is hardly likely to know, and perhaps HC is not the principal source of market information.

There is clearly a great opportunity for PRR to announce that recruiting for phase III while phase II is underway is such a favourable development, including what Philbar describes in his post.

Hard to see why the week would end without such an announcement.

It is worth following the link below to the site boiler referred to. It gives the phase III end-date of Dec 2015 and provides a short description of the primary outcome measure of the trial:

'•Progression-free survival (PFS) for maintenance treatment of patients with EOC in complete remission following first-line chemotherapy'

http://clinicaltrials.gov/ct2/show/NCT01521143?term=cvac&rank=2

It seems to increase the chances that the apparent confidence of PRR that - it does work, we just need to prove it - is well placed. As external observers we only have the the limited statistical value of the previous trial which at least included some instances of PFS.

It is a long path to follow and it is reassuring to see another firm step in the right direction.

Again, thanks for bringing it the forum.

cheers